Contract Development and Manufacturing (CDMO) Market to Reach USD 280.07 Billion by 2033 | CAGR 7.4% | North America Leads with 38% Share | Key Players: Recipharm, Jubilant Pharmova, Boehringer Ingelheim

Market Overview

The global Contract Development and Manufacturing (CDMO) market reached US$ 150.19 billion in 2024 and is projected to reach US$ 280.07 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033. A Contract Development and Manufacturing Organization (CDMO) plays a critical role in the pharmaceutical and biotechnology industries, offering end-to-end services across drug development, formulation, manufacturing, and packaging. These organizations enable pharmaceutical and biotech firms to optimize operations by outsourcing technical and production processes, reducing time-to-market and operational expenses.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/contract-development-and-manufacturing-market?Juli

Recent Developments:

✅ November 2025: A leading global CDMO expanded its biologics manufacturing facility in North America, adding new single-use bioreactor capacity to support cell- and gene therapy production.

✅ August 2025: A major European CDMO launched a continuous manufacturing platform for small molecules, aimed at reducing production cycle times and improving regulatory compliance.

✅ June 2025: A top biotechnology CDMO entered a strategic collaboration with a global pharmaceutical firm to co-develop and scale up manufacturing of next-generation RNA-based therapeutics.

✅ March 2025: A CDMO consortium unveiled an integrated end-to-end digital quality and regulatory compliance system to streamline documentation and accelerate product approvals.

✅ January 2025: A prominent CDMO announced a new high-containment facility dedicated to manufacturing complex biologics and vaccines, addressing rising demand from emerging markets.

Mergers & Acquisitions:

✅ October 2025: A leading North American CDMO acquired a European biologics manufacturer to expand its global footprint and enhance end-to-end capabilities for monoclonal antibody and cell therapy production.

✅ July 2025: A global pharmaceutical CDMO completed the acquisition of a specialized peptide and oligonucleotide manufacturer to strengthen its advanced API development and manufacturing portfolio.

✅ May 2025: A major Asian CDMO acquired a U.S. small-molecule contract manufacturer, enhancing its capacity for clinical and commercial-scale chemical synthesis.

✅ March 2025: Two mid-tier CDMOs merged to form a new entity focused on scalable aseptic fill-finish services and biologics packaging for vaccines and large-molecule drugs.

✅ January 2025: An established CDMO group acquired a specialized regulatory and quality compliance consultancy to deepen its expertise in global submissions and accelerate time-to-market for complex therapies.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=contract-development-and-manufacturing-market?Juli

Key Players:
Catalent Inc. | Recipharm AB | Jubilant Pharmova Limited | Thermo Fisher Scientific Inc. | Boehringer Ingelheim International GmbH | IQVIA | Syneos Health | Parexel International (MA) Corporation | Curia Global, Inc. | NextPharma Technologies

Key Highlights:

• Catalent Inc. - Holds a 16.3% market share, leading the CDMO space with a robust portfolio across biologics, gene therapy, and oral dosage manufacturing. The company continues to expand its global biologics and cell therapy production capacity to serve pharmaceutical and biotech innovators.

• Recipharm AB - Holds a 12.8% share, driven by its strong European manufacturing footprint and expertise in injectables, inhalation products, and oral solid dosage formulations. Continuous investments in sterile operations and sustainable manufacturing strengthen its global position.

• Jubilant Pharmova Limited - Holds a 9.6% share, supported by its comprehensive capabilities in drug discovery, contract research, and formulation development, particularly in emerging markets across Asia and North America.

• Thermo Fisher Scientific Inc. - Holds a 15.4% share, benefiting from its integrated pharma services platform offering API development, biologics production, and commercial manufacturing solutions for large pharmaceutical firms and biotech startups alike.

• Boehringer Ingelheim International GmbH - Holds a 10.2% share, driven by its leadership in large-scale biopharmaceutical contract manufacturing and microbial production under the BioXcellence brand.

• IQVIA - Holds an 8.7% share, leveraging its advanced data analytics and clinical trial management capabilities to deliver integrated CDMO-CRO solutions that optimize clinical and commercial success.

• Syneos Health - Holds a 7.5% share, offering hybrid services that combine contract research and manufacturing to provide seamless drug development and commercialization solutions.

• Parexel International (MA) Corporation - Holds a 7.1% share, supported by strong regulatory, clinical, and manufacturing collaborations, particularly for biologics and small-molecule drug development.

• Curia Global, Inc. - Holds a 6.3% share, focusing on small-molecule API synthesis, biologics production, and integrated R&D services, catering to global pharmaceutical and biotech clients.

• NextPharma Technologies - Holds a 6.1% share, specializing in oral solid dosage and sterile manufacturing with flexible capacity expansion across European facilities.

Market Segmentation:

➥ By Service Type, Active Pharmaceutical Ingredient (API) Manufacturing dominates with a 45% share, driven by increasing outsourcing of small- and large-molecule API production to reduce cost and time-to-market. The demand for biologics APIs and high-potency active pharmaceutical ingredients (HPAPIs) continues to rise, supported by advanced technology platforms and strict regulatory compliance. Finished Dosage Formulation (FDF) Development and Manufacturing accounts for 40%, fueled by growing requirements for oral solids, injectables, and sterile manufacturing. Secondary Packaging represents 15%, driven by customized labeling, serialization, and compliance with evolving global packaging regulations.

➥ By Research Phase, Phase III leads with a 35% share, as most outsourcing contracts are focused on late-stage clinical trials that require large-scale manufacturing and regulatory documentation support. Phase II follows with 25%, where CDMOs support formulation optimization and scale-up. Pre-Clinical accounts for 15%, driven by early-stage API synthesis and analytical development services. Phase I holds a 10% share, mainly for pilot manufacturing and toxicology batch preparation, while Phase IV post-marketing support represents 15%, focusing on commercial-scale manufacturing, reformulation, and lifecycle management.

➥ By End User, Pharmaceutical Companies dominate with a 60% share, leveraging CDMOs to reduce infrastructure costs and focus on R&D and marketing. Contract Research Organizations (CROs) account for 25%, outsourcing manufacturing partnerships to support integrated drug development workflows. Generic Pharmaceutical Companies represent 15%, utilizing CDMOs for cost-effective formulation development, production, and regulatory filing support across global markets.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/contract-development-and-manufacturing-market?Juli

Market Dynamics:

Driver:
The growing demand for pharmaceutical and biopharmaceutical products is a key factor propelling the expansion of the global Contract Development and Manufacturing (CDMO) market. The increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disorders, and autoimmune conditions is driving the need for large-scale, efficient, and compliant manufacturing capabilities. As the global population continues to age and lifestyle-related diseases become more prevalent, pharmaceutical and biotechnology companies face mounting pressure to accelerate drug discovery, clinical development, and commercialization. This has led to a surge in outsourcing to CDMOs that possess the specialized infrastructure, regulatory expertise, and technological capabilities needed to streamline complex production processes.

For example, in October 2024, Samsung Biologics launched its S-HiConTM high-concentration formulation platform to enhance the development and production of high-dose biopharmaceuticals. The technology stabilizes formulations, minimizes viscosity, and ensures optimal drug delivery efficiency, reflecting the industry's shift toward advanced biologic formulations. Similarly, the adoption of continuous manufacturing technologies is transforming the CDMO landscape by improving efficiency, reducing production waste, and lowering overall drug manufacturing costs. In October 2024, Enzene Biosciences introduced EnzeneX 2.0, an extension of its fully integrated continuous manufacturing (FCCM) platform designed for commercial biologics supply a breakthrough that further demonstrates the integration of next-generation production technologies in CDMO operations.

Additionally, the global trend toward strategic outsourcing continues to shape the CDMO industry. Pharmaceutical and biotechnology firms increasingly rely on CDMOs to handle specialized tasks such as process optimization, scale-up, and analytical development, allowing them to focus on R&D and commercialization. In November 2024, Siegfried AG inaugurated a new global R&D center for pharmaceutical compounds at its Evionnaz site in Switzerland. The 4,500 m2 facility is equipped with advanced process analytics, flow chemistry systems, and pilot-scale manufacturing capabilities to support chemical synthesis, viral vector research, and analytical services for biologics and cell therapies. These initiatives exemplify how CDMOs are evolving into innovation-driven partners capable of managing end-to-end development and manufacturing processes.

Restraint:
Despite the market's growth momentum, the CDMO sector faces restraints due to the high capital investment and operational costs required for advanced manufacturing technologies. Establishing compliant facilities that meet regulatory standards for biologics, cell, and gene therapy production demands significant expenditure in equipment, cleanroom environments, and validation processes. Furthermore, the transition toward continuous and modular manufacturing systems increases the need for specialized expertise and training, further elevating operational complexity.

Regional Insights:

North America dominates the global CDMO market, accounting for 38% of total revenue (US$ 57.07 billion in 2024), driven by the strong presence of established pharmaceutical and biotechnology companies, advanced R&D infrastructure, and a high rate of outsourcing among major drug developers. The U.S. leads the region, supported by extensive investments in biologics, cell, and gene therapies, coupled with the early adoption of continuous and modular manufacturing systems. The region also benefits from a robust regulatory framework under the U.S. FDA, ensuring quality and compliance, which further strengthens CDMO-pharma collaborations.

Europe holds a 28% market share (US$ 42.05 billion in 2024), supported by a growing network of CDMOs specializing in sterile manufacturing, API production, and biosimilar development. The region's strong biopharmaceutical cluster particularly in countries such as Germany, Switzerland, Ireland, and the UK is driving innovation in advanced drug delivery systems and formulation development. Favorable government initiatives promoting life sciences investment, coupled with an emphasis on sustainability and digital manufacturing, are fostering growth across the European CDMO sector.

Asia-Pacific is the fastest-growing region, accounting for 26% of the market (US$ 39.04 billion in 2024) and projected to register a CAGR of over 9.5% during 2025-2033. The region's expansion is driven by cost advantages, skilled labor availability, and increasing pharmaceutical manufacturing capacity in China, India, South Korea, and Singapore. Major global CDMOs are expanding operations in Asia to meet rising demand for biologics and small-molecule APIs, with governments offering tax incentives and infrastructure support for local production. India and China, in particular, are emerging as strategic manufacturing hubs for both global and regional pharmaceutical companies.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.